VIRGINIA RETIREMENT SYSTEMS ET Al Invests $48.55 Million in IDEXX Laboratories, Inc. $IDXX

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 92,218 shares of the company’s stock, valued at approximately $48,547,000.

Other large investors have also made changes to their positions in the company. California State Teachers Retirement System grew its stake in IDEXX Laboratories by 50,115.1% in the second quarter. California State Teachers Retirement System now owns 61,590,848 shares of the company’s stock valued at $32,423,886,000 after acquiring an additional 61,468,194 shares during the period. Saudi Central Bank raised its position in shares of IDEXX Laboratories by 88.7% during the second quarter. Saudi Central Bank now owns 5,560 shares of the company’s stock worth $2,927,000 after purchasing an additional 2,613 shares during the period. AlphaGrep UK Ltd acquired a new stake in shares of IDEXX Laboratories during the second quarter worth about $1,385,000. Maloon Powers Pitre Higgins & Dennehy LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $303,000. Finally, Plan A Wealth LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $203,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $535.38 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock has a market capitalization of $42.18 billion, a P/E ratio of 37.65, a P/E/G ratio of 2.86 and a beta of 1.54. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The business has a 50-day moving average of $558.27 and a 200-day moving average of $570.05.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup increased their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, UBS Group raised their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.